A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor.

MedStar author(s):
Citation: Immunotherapy. 12(12):861-867, 2020 08.PMID: 32640856Institution: MedStar Washington Hospital CenterDepartment: Internal Medicine Residency | Pathology ResidencyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Antibodies, Monoclonal, Humanized/tu [Therapeutic Use] | *Antineoplastic Agents/tu [Therapeutic Use] | *Imidazoles/tu [Therapeutic Use] | *Immunotherapy/mt [Methods] | *Melanoma/dt [Drug Therapy] | *Oximes/tu [Therapeutic Use] | *Pyridones/tu [Therapeutic Use] | *Pyrimidinones/tu [Therapeutic Use] | Antibodies, Monoclonal, Humanized/im [Immunology] | Antineoplastic Agents/im [Immunology] | Cyclin-Dependent Kinase 4/ai [Antagonists & Inhibitors] | Cyclin-Dependent Kinase 4/im [Immunology] | Cyclin-Dependent Kinase 6/ai [Antagonists & Inhibitors] | Cyclin-Dependent Kinase 6/im [Immunology] | Humans | Imidazoles/im [Immunology] | Male | Melanoma/im [Immunology] | Middle Aged | Oximes/im [Immunology] | Pyridones/im [Immunology] | Pyrimidinones/im [Immunology] | Treatment OutcomeYear: 2020ISSN:
  • 1750-743X
Name of journal: ImmunotherapyAbstract: Background: Despite the profound effect that checkpoint inhibitors and BRAF/MEK inhibitors have had on survival in patients with metastatic melanoma, treatment options remain limited for those who demonstrate poor response or develop resistance to these modalities. The prospect of tumor sensitization to these treatments is therefore an attractive one. Results: We describe the case of a patient who developed a sustained response to trametinib and pembrolizumab, despite prior resistance to both these therapies, after receiving treatment with a CDK4/6 inhibitor. Discussion: We further outline the preclinical data supporting a possible role for the use of CDK4/6 inhibitors in tumor sensitization to immunotherapy.All authors: Alzeer A, Atkins M, Villa K, Zaemes JOriginally published: Immunotherapy. 12(12):861-867, 2020 08.Fiscal year: FY2021Fiscal year of original publication: FY2021Digital Object Identifier: Date added to catalog: 2020-09-02
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 32640856 Available 32640856

Background: Despite the profound effect that checkpoint inhibitors and BRAF/MEK inhibitors have had on survival in patients with metastatic melanoma, treatment options remain limited for those who demonstrate poor response or develop resistance to these modalities. The prospect of tumor sensitization to these treatments is therefore an attractive one. Results: We describe the case of a patient who developed a sustained response to trametinib and pembrolizumab, despite prior resistance to both these therapies, after receiving treatment with a CDK4/6 inhibitor. Discussion: We further outline the preclinical data supporting a possible role for the use of CDK4/6 inhibitors in tumor sensitization to immunotherapy.

English

Powered by Koha